• Dyne Therapeutics director Jason P. Rhodes reported sales of 267,760 common shares on June 23-25 under a Rule 10b5-1 plan.
• Shares sold at weighted-average prices of USD 21.13, USD 21.02, USD 21.1 across the three days.
• Post-transaction holdings: 4,742,410 shares via Atlas Venture Fund XI; 1,478,378 via Atlas Venture Opportunity Fund II; 1,081,044 via Atlas Venture Opportunity Fund I.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001577014-26-000010), on June 26, 2026, and is solely responsible for the information contained therein.